Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.
The event is scheduled for June 4, 2026 at 2:00 PM ET, with a live and archived webcast available on Aclaris’ website for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ACRS
In the May 28 session, ACRS declined 0.22%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 08 | Conference participation | Neutral | +1.4% | Announced presentation at Bank of America Healthcare Conference with webcast access. |
| May 07 | Earnings & update | Positive | +1.7% | Q1 2026 results with positive ATI-052 data and strong cash position through 2028. |
| Apr 28 | Clinical data update | Positive | -4.3% | Positive full top-line Phase 1a ATI-052 results and ATI-2138 indication decision. |
| Apr 27 | Upcoming data call | Neutral | -4.3% | Planned April 28 clinical update webcast for ATI-052 and ATI-2138 programs. |
| Apr 08 | Conference participation | Neutral | +5.3% | Participation in H.C. Wainwright inflammatory skin disease conference with webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, especially conferences and updates, often aligned with positive price reactions, but key clinical data in April saw a negative divergence.
Over the past two months, Aclaris has mixed corporate and clinical milestones. On April 28, it reported positive Phase 1a data for ATI‑052 and advanced ATI‑2138, yet the stock fell about 4.31%, mirroring a similar decline after the April 27 clinical update preview. In contrast, Q1 2026 results on May 7 and multiple conference participation announcements on April 14 and May 14 were followed by gains between roughly 1–5%. Today’s Jefferies conference participation fits this pattern of incremental, communication-focused news flow.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY.
A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
